Research
We use a new innovative lab model made up of human neuroendocrine cancer and fibroblasts that we grow in human protein scaffolds/gels derived from the scar tissue and the cancer of the patient collected after surgery, mimicking much better the human cancer and this to explore/identify therapeutic mechanisms to target cancer cells and their surrounding cells to stop the scar tissue formation and cancer growth. 2. Feasibility of cell-free DNA methylation profiling for minimally invasive cancer detection and classification in patients with well-differentiated neuroendocrine tumours. Dr Melissa Frizziero, The Christie NHS Foundation Trust, Manchester. Diagnosing neuroendocrine neoplasms (NENs) and identifying the correct subtype (which dictates the choice of treatment) can be difficult using tissue biopsies that only collect a small piece of tumour tissue and are technically challenging to perform. This project aims to test whether a new technology examining DNA from a simple blood draw (cell-free DNA) can improve the diagnosis of NENs, offering patients a better chance to receive the best treatment.
Prof Krista Rombouts, Royal Free Hospital, London
Dr Melissa Frizziero, The Christie NHS Foundation Trust, Manchester
www.neuroendocrinecancer.org.uk
Made with FlippingBook - Online magazine maker